Abstract:
The present invention provides a pharmaceutical composition to improve or treat muscle atrophy disease comprising stem cells derived from umbilical cord as an active ingredient. Upon administering the stem cells derived from umbilical cord of the present invention into muscles, the administered stem cells increase the muscle cells in stem cell administered areas and increase muscle fiber size and myotility, thus the stem cells derived from umbilical cord can be effective to improve or treat muscle atrophy disease. The stem cells derived from the umbilical cord of the present invention are cultivated in a medium including an umbilical cord extract as a replacement, thereby being safely applicable clinically without concerns of safety problems such as cross-species contamination according to use of fetal bovine serum and the like.